Resources

This joint capacity statement showcases how PATH works to unite the historically siloed sectors of primary health care (PHC) and epidemic preparedness and response (EPR) to build more resilient health systems. By combining PATH's technical capacities and experience in preventive health services, surveillance, data management, and response, we are able to more effectively partner with countries to address infectious disease epidemics, impacts from climate-change, antimicrobial resistance, and other emerging barriers to health equity.

In 2020, Ghana switched from using ROTARIX® to ROTAVAC® in its national immunization program. PATH worked with Ghana Health Service and the University of Ghana to analyze the economic implications of this switch. These four fact sheets explore the key results of these analyses, collectively providing a case study on Ghana’s rotavirus vaccine product switch.(Manuscript pending submission to a peer-reviewed journal.)

In India, PATH supports the development of user-centric digital health tools for effective data management in human milk banks across India. This fact sheet details one such intervention which records, processes, and analyzes the end-to-end process of human milk banking

This brief summarizes a comprehensive review and assessment of current, published evidence for a single-dose HPV vaccination schedule. The review was undertaken by researchers in the Single-Dose HPV Vaccine Evaluation Consortium.Visit the Single-Dose HPV Vaccine Evaluation Consortium page for additional resources.

La incidencia del cáncer de mama aumenta constantemente en los países de ingresos bajos y medianos a medida que aumenta la esperanza de vida de las mujeres y los estilos de vida cambian y aumentan los factores de riesgo de cáncer de mama. Al igual que con otras enfermedades, la carga recae más sobre los pobres, los marginados y las mujeres rurales debido al acceso desigual a la detección y el tratamiento. Es bien conocida la importancia de la detección temprana y el tratamiento del cáncer de mama, el costo y el éxito del tratamiento están directamente relacionados con el estadio del cáncer al momento del diagnóstico.